Form 6-K BioLineRx Ltd. For: Aug 11

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. TSCO
9. BE
10. SLM

Go back to Form 6-K BioLineRx Ltd. For: Aug 11

Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession

August 11, 2016 11:46 AM EDT

Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.

Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More

BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones

August 11, 2016 7:19 AM EDT

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).

Expected upcoming significant milestones for remainder of 2016:

Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3... More